Rituximab plus chemotherapy in follicular and mantle cell lymphomas

被引：45

作者：

Hiddemann, W ^{[1
]}

Dreyling, M ^{[1
]}

Unterhalt, M ^{[1
]}

机构：

[1] Univ Munich, Klinikum Grosshadern, Med Klin 3, D-81377 Munich, Germany

来源：

SEMINARS IN ONCOLOGY | 2003年 / 30卷 / 01期

关键词：

D O I：

10.1053/sonc.2003.50024

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：16 / 20

页数：5

共 26 条

[1]

Alas S, 2000, ANTICANCER RES, V20, P2961

[2] Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe D'Etude des Lymphomes Folliculaires [J].

Brice, P ;

Bastion, Y ;

Lepage, E ;

Brousse, N ;

Haioun, C ;

Moreau, P ;

Straetmans, N ;

Tilly, H ;

Tabah, I ;

SolalCeligny, P .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) :1110-1117

[3] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[4] Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden:: clinical and molecular evaluation [J].

Colombat, P ;

Salles, G ;

Brousse, N ;

Eftekhari, P ;

Soubeyran, P ;

Delwail, V ;

Deconinck, E ;

Haïoun, C ;

Foussard, C ;

Sebban, C ;

Stamatoullas, A ;

Milpied, N ;

Boué, F ;

Taillan, B ;

Lederlin, P ;

Najman, A ;

Thièblemont, C ;

Montestruc, F ;

Mathieu-Boué, A ;

Benzohra, A ;

Solal-Céligny, P .

BLOOD, 2001, 97 (01) :101-106

[5] Rituximab in combination with CHOP or fludarabine in low-grade lymphoma [J].

Czuczman, MS ;

Fallon, A ;

Mohr, A ;

Stewart, C ;

Bernstein, ZP ;

McCarthy, P ;

Skipper, M ;

Brown, K ;

Miller, K ;

Wentling, D ;

Klippenstein, D ;

Loud, P ;

Rock, MK ;

Benyunes, M ;

Grillo-López, AJ ;

Bernstein, SH .

SEMINARS IN ONCOLOGY, 2002, 29 (01) :36-40

[6]

Czuczman MS, 2001, BLOOD, V98, p601A

[7] Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy [J].

Czuczman, MS ;

Grillo-López, AJ ;

White, CA ;

Saleh, M ;

Gordon, L ;

LoBuglio, AF ;

Jonas, C ;

Klippenstein, D ;

Dallaire, B ;

Varns, C .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :268-276

[8] LONG-TERM FOLLOW-UP OF PATIENTS WITH LOW-GRADE MALIGNANT-LYMPHOMAS TREATED WITH DOXORUBICIN-BASED CHEMOTHERAPY OR CHEMOIMMUNOTHERAPY [J].

DANA, BW ;

DAHLBERG, S ;

NATHWANI, BN ;

CHASE, E ;

COLTMAN, C ;

MILLER, TP ;

FISHER, RI .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (04) :644-651

[9] Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma:: Results of a phase II trial of rituximab [J].

Davis, TA ;

White, CA ;

Grillo-López, AJ ;

Velásquez, WS ;

Link, B ;

Maloney, DG ;

Dillman, RO ;

Williams, ME ;

Mohrbacher, A ;

Weaver, R ;

Dowden, S ;

Levy, R .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (06) :1851-1857

[10] Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma:: Safety and efficacy of re-treatment [J].

Davis, TA ;

Grillo-López, AJ ;

White, CA ;

McLaughlin, P ;

Czuczman, MS ;

Link, BK ;

Maloney, DG ;

Weaver, RL ;

Rosenberg, J ;

Levy, R .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3135-3143

← 1 2 3 →